Novavax
Clinical development pipeline, platform architecture, and registered trial tracking for Novavax vaccine candidates.
Development Phase Distribution
Platform Technologies
Target Pathogens & Indications
Vaccine Pipeline Candidates (7)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
NUVAXOVID
Target: COVID-19
Platform: Licensed biologic (see FDA product page)
NVX-CoV2705
Target: COVID-19
Platform: Biological (unspecified platform)
NanoFlu (Quad-NIV, Matrix-M)
Target: Influenza
Platform: Biological (unspecified platform)
Novavax CIC (COVID-19-Influenza Combination; SARS-CoV-2 rS + tNIV, Matrix-M)
Target: COVID-19
Platform: Biological (unspecified platform)
SII B.1.351
Target: COVID-19
Platform: Biological (unspecified platform)
tNIV 1 and Matrix-M Adjuvant
Target: COVID-19
Platform: Protein / subunit
COVID-Influenza Combination (CIC) — Novavax
Target: Seasonal influenza + COVID-19 (combination)
Platform: Protein nanoparticle + Matrix-M
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.